ZLDPF Zealand Pharma A/S

$38.10

Zealand Pharma A/S (ZLDPF) is expected to report earnings on November 12, 2026, before the market open. The consensus earnings estimate is a loss of $1.33 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -27.7% since its last earnings release on August 13, 2026.

Zealand Pharma A/S Beat Consensus Estimates
Thursday, August 13, 2026 · 12:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 12
Thursday · Before Open
Earnings Whisper
-
vs ($1.33)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $47.23

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Zealand Pharma A/S

Zealand Pharma A/S is a biotechnology company. It focused on the discovery, design and development of peptide-based medicines. The company's pipeline includes ZP4207, single-dose rescue treatment for acute, severe hypoglycemia; ZP1848 for short bowel syndrome and ZP4207, multiple-dose version intended for use in a dual-hormone artificial pancreas system for better hypoglycemia control and diabetes management and other earlier-stage clinical and preclinical peptide therapeutics are in clinical stage. Zealand Pharma A/S is based in Copenhagen, Denmark.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.